MRVI Q4 2023 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$74M-63.8% YoY

Gross Profit

$39M52.6% margin

Operating Income

-$7M-9.6% margin

Net Income

-$106M-142.9% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+10.9%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

-$9M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$698M

Stockholders' Equity

$417M

Cash & Equivalents

$575M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$74M	$205M	-63.8%
Gross Profit	$39M	$151M	-74.2%
Operating Income	-$7M	$109M	-106.5%
Net Income	-$106M	$38M	-381.6%

Revenue Segments

Nucleic Acid Production Segment

$59M79%

Biologics Safety Testing Segment

$15M21%

Geographic Segments

North America

$107M48%

Asia Pacific

$73M33%

EMEA

$42M19%

Latin And Central America

$422,0000%